DUBLIN, IRELAND--(MARKET WIRE)--Apr 2, 2008 -- Trinity Biotech plc (NasdaqGS:TRIB - News), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets and the market leader in adult haemoglobinopathy detection, is pleased to announce the introduction of its GeneSys(TM) platform for infant haemoglobinopathies. The GeneSys(TM) system will be the first on the market to offer a fully automated approach for newborn screening while providing positive identification for all major infant haemoglobin variants. The system also offers the unique time saving capability of allowing laboratories to run a confirmatory test on the same instrument for all positive results.

In the U.S. under Federal Law, it is mandatory to screen all newborns for haemoglobinopathies. As a result, over 4 million newborns in the U.S. each year are tested for genetic blood disorders, some of which have significant long term clinical implications. Demand is currently served by a small number of market participants. Trinity will market the GeneSys(TM) system to the 38 U.S. State laboratories that participate in the national neonatal screening program immediately upon its release.

"The Trinity GeneSys(TM) platform provides a number of competitive advantages to the alternative products currently used by U.S. State laboratories. It is the only platform to provide truly automated sample handling. It provides screening results in two minutes and it enables confirmatory tests to be run on the same instrument," commented Brendan K. Farrell CEO of Trinity Biotech. "Trinity Biotech is particularly pleased to bring our market leading technology from the adult haemoglobinopathy market to the neonatal market. We believe that the product will prove an immediate success and this week are shipping our first two instruments to a State laboratory."

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and blood coagulation disorders, and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.

     Contact :
     Trinity Biotech plc
     Brendan Farrell
     (353)-1-2769800
     E-mail: Email Contact